Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Lost Money in NovoCure Limited? Gibbs Law Group Investigates Potential Securities Law Violations

Gibbs Law Group announces that a class action lawsuit has been filed on behalf of NovoCure Limited (NASDAQ: NVCR) investors. On June 6, 2023, NovoCure announced results from its Phase 3 LUNAR clinical trial that some doctors say may have included unreliable data, because not all study participants had been receiving standard of care therapy, according to Evaluate. Gibbs Law Group encourages NovoCure investors to contact us to discuss their legal rights and options.

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On June 6, 2023, global oncology company NovoCure Limited presented results from its Phase 3 LUNAR clinical trial evaluating the safety and efficacy of its Tumor Treating Fields therapy. Doctors and attendees of a June 6 American Society of Clinical Oncology conference subsequently pointed out that the data set used in the study may not be fully reliable in showing clinical efficacy, because the therapy was mostly tested in patients whose conditions worsened following chemotherapy, which is no longer the standard of care, according to Investor’s Business Daily. One doctor who was present at NovoCure’s June 6 presentation stated that “the study design does not reflect the current standard of care,” with another doctor agreeing that “its relevance to the majority of patients in 2023 is yet to be demonstrated,” as reported by Evaluate.

NovoCure released 2023 Q2 financial results on July 27, 2023, reporting a $57.4 million loss in its’ second quarter. Yahoo Finance analysts noted that “[a]head of this earnings release, the estimate revisions trend for NovoCure: unfavorable,” and that the “shares are expected to underperform the market in the near future.”

On this news, NovoCure’s stock price plummeted 43% on June 6, 2023, causing significant harm to investors.

What Should NovoCure Limited Investors Do?

If you invested in NovoCure Limited visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether NovoCure Limited has violated federal securities laws by providing false or misleading statements to investors.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.